Agilent Technologies (A) Aperçu de l'action
Agilent Technologies, Inc. fournit des solutions axées sur les applications aux marchés des sciences de la vie, du diagnostic et de la chimie appliquée dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 2/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
Aucun risque n'a été détecté pour A à partir de nos contrôles de risques.
A Community Fair Values
Create NarrativeSee what 47 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
ST
Fair Value from
US$21.5363.5% sous-évalué décote intrinsèque
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeAgilent Technologies, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$118.65 |
| Plus haut sur 52 semaines | US$160.27 |
| Plus bas sur 52 semaines | US$106.55 |
| Bêta | 1.22 |
| Variation sur 1 mois | 4.19% |
| Variation sur 3 mois | -8.43% |
| Variation sur 1 an | 9.15% |
| Variation sur 3 ans | -7.06% |
| Variation sur 5 ans | -8.74% |
| Évolution depuis l'introduction en bourse | 177.54% |
Nouvelles et mises à jour récentes
Mise à jour de l'analyse • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.Mise à jour de l'analyse • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Recent updates
Mise à jour de l'analyse • Apr 25
A: New Diagnostic Approvals And Buybacks Will Support Long Term Upside
Analysts have trimmed their price target on Agilent Technologies by about $1 to $160.69, reflecting slightly adjusted views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News The Supreme Court of the United States denied Agilent Technologies' petition related to two CRISPR guide RNA patents, leaving in place prior rulings that found all claims of the patents unpatentable.Mise à jour de l'analyse • Apr 09
A: New Diagnostic Expansion And Guidance Will Support Long Term Upside
Analysts have slightly reduced their price target on Agilent Technologies by about $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. They indicate that the overall outlook remains largely intact.Mise à jour de l'analyse • Mar 26
A: New Diagnostic Approval Will Drive Upside For Long Term Outlook
Analysts have made a slight trim to their price target for Agilent Technologies to about $163.19 from around $163.29, citing updated assumptions for revenue growth, profit margins and a somewhat lower future P/E multiple. What's in the News The FDA approved Agilent's PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to help identify first line patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma who may be eligible for treatment with KEYTRUDA, adding a seventh companion diagnostic indication for this assay (Key Developments).Mise à jour de l'analyse • Mar 11
A: New Diagnostic Approvals And Digital Pathology Expansion Will Drive Upside
Analysts have trimmed their price target on Agilent Technologies to about $163 from roughly $170, citing modest tweaks to their models, including slightly adjusted revenue growth, discount rate, profit margin, and future P/E assumptions. What's in the News Agilent issued earnings guidance for fiscal Q2 2026, with revenue expected in the range of $1.79b to $1.82b, framed as approximately 7% to 9% reported growth and 4% to 5.5% core growth (company guidance).Seeking Alpha • Mar 10
Why Agilent Technologies Just Paid $950 Million For Biocare Medical
Summary Agilent Technologies (A) acquires Biocare Medical for $950M to expand into high-growth pathology and cancer diagnostics, enhancing recurring consumables revenue streams. A trades below historical valuation multiples, presenting an opportunity if management executes on diagnostics expansion and leverages its global distribution to scale Biocare’s offerings. 1Q26 results showed 7% reported revenue growth to $1.80B, with non-GAAP EPS up 4% year-over-year, and management raised FY26 guidance for both revenue and EPS. The Biocare deal accelerates Agilent’s shift toward higher-margin, recurring revenue, with management expecting positive EPS contribution within 12 months post-close. Read the full article on Seeking AlphaMise à jour de l'analyse • Feb 25
A: New Diagnostic Approvals Will Support Measured Upside Ahead
Analysts reaffirm a price target of $169.67 for Agilent Technologies, citing largely unchanged assumptions for the discount rate, revenue growth, profit margin, and future P/E. These factors together keep their valuation framework intact.Mise à jour de l'analyse • Feb 10
A: New Digital Pathology And Board Declassification Will Support Measured Upside Ahead
Analysts have modestly trimmed their price target on Agilent Technologies to reflect slightly higher discount rate assumptions and a lower future P/E, while still incorporating steady revenue growth and a marginally stronger profit margin outlook. What's in the News Agilent plans to ask shareholders at the March 18, 2026 AGM to approve an amendment to its Third Amended and Restated Certificate of Incorporation that would declassify the board of directors over three years, shifting toward annual director elections (Key Developments).Mise à jour de l'analyse • Jan 26
A: New Digital Pathology And Buybacks Will Support Measured Upside Ahead
Analysts have nudged their price target on Agilent Technologies slightly higher to about US$170, citing updated assumptions around fair value, discount rates, revenue growth, profit margins and future P/E, which collectively support a modest upward revision. What's in the News Agilent launched the S540 MD Slide Scanner System for whole slide imaging in key European markets, adding a high throughput digital pathology scanner with capacity for 540 slides and AI assisted tissue detection to its portfolio (Product Related Announcements).Mise à jour de l'analyse • Jan 11
A: New CFO And Capital Returns Will Support Measured Upside Ahead
Analysts have nudged their price target for Agilent Technologies slightly lower to US$168.59 from US$169.44, citing small adjustments to their fair value estimate, discount rate, revenue growth outlook, profit margin assumptions, and future P/E expectations. What's in the News Agilent outlined fiscal first quarter 2026 revenue guidance of US$1.79b to US$1.82b and fiscal 2026 revenue guidance of US$7.3b to US$7.4b, with both ranges expressed in reported and core terms (Corporate guidance).Article d'analyse • Dec 18
Agilent Technologies (NYSE:A) Is Increasing Its Dividend To $0.255
Agilent Technologies, Inc. ( NYSE:A ) has announced that it will be increasing its dividend from last year's comparable...Mise à jour de l'analyse • Dec 15
A: New Leadership And Compliance Software Will Support Measured Upside Ahead
Analysts have nudged their average price target on Agilent Technologies higher by about $2 to roughly $169.44, citing slightly faster expected revenue growth and a modestly lower discount rate that more than offset a small downward revision to long term profit margins. What's in the News Launched 21 CFR Part 11 compliant software for the xCELLigence RTCA eSight system, enabling secure deployment in GMP manufacturing and QC labs with features such as secure logins, e-signatures, and full audit trails (Key Developments).Mise à jour de l'analyse • Nov 30
A: New Diagnostic Solutions And Leadership Will Shape Measured Prospects Ahead
Analysts have raised their price target for Agilent Technologies from $152.33 to $167.57, citing modestly higher expectations for revenue growth and valuation metrics as the primary reasons for the change. What's in the News Agilent Technologies provided earnings guidance for fiscal Q1 2026, expecting revenue in the range of $1.79 billion to $1.82 billion, up 6% to 8% reported and 4% to 6% core.Article d'analyse • Nov 27
Agilent Technologies, Inc. (NYSE:A) Analysts Are Pretty Bullish On The Stock After Recent Results
It's been a good week for Agilent Technologies, Inc. ( NYSE:A ) shareholders, because the company has just released its...Mise à jour de l'analyse • Nov 16
A: Product Launches And Diagnostic Approval Will Support Balanced Outlook
Narrative Update: Agilent Technologies Analyst Price Target Revision Analysts have raised their price target for Agilent Technologies from $149.90 to $152.33. This change reflects modest upward revisions in projected revenue growth and a slightly higher expected future valuation multiple.Mise à jour de l'analyse • Nov 01
A: Global Healthcare Trends And New Diagnostic Solutions Will Shape Future Performance
Analysts have slightly raised their price target for Agilent Technologies from $148.57 to $149.90, citing stable fundamentals and a modest valuation adjustment. What's in the News Adam S.Mise à jour de l'analyse • Oct 18
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Analysts have raised their price target for Agilent Technologies from $140.97 to $148.57, citing improved revenue growth prospects and higher expected profit margins as key drivers behind the upward revision. What's in the News Announced launch of Insight Series Alarm Resolution Systems, which enhance airport security checkpoints with advanced liquid explosive detection and adaptability to changing regulations (Product Related Announcements).Mise à jour de l'analyse • Oct 04
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies received a modest analyst price target increase from $138.83 to $140.97. This reflects analysts' expectations for stable growth and slightly improved long-term valuation metrics.Mise à jour de l'analyse • Sep 16
Global Healthcare Demand And PFAS Testing Will Drive Analytical Progress
Agilent Technologies’ fair value estimates have remained stable, as reflected by marginal changes in both the consensus analyst price target (up slightly to $138.83) and the forward P/E (now 27.33x). What's in the News Raised full-year 2025 revenue guidance to $6.91–$6.93 billion, up 6.2–6.5% reported and 4.3–4.6% core, reflecting a $150 million increase at the midpoint and 1.5 points higher core growth.Article d'analyse • Aug 03
Estimating The Intrinsic Value Of Agilent Technologies, Inc. (NYSE:A)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Agilent Technologies fair value estimate is US$114 With US$114...Article d'analyse • Jul 01
What Is Agilent Technologies, Inc.'s (NYSE:A) Share Price Doing?
Today we're going to take a look at the well-established Agilent Technologies, Inc. ( NYSE:A ). The company's stock saw...Seeking Alpha • Apr 24
City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto
Summary City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures. Despite macroeconomic risks, Series A's deep discount and commendable yield, along with manageable leverage ratios, led to us deeming it a 'Buy.' Read the full article on Seeking AlphaSeeking Alpha • Apr 07
Tariffs And Tactics: Agilent's Path Through Trade Disruption
Summary The April 2025 "Liberation Day" tariffs impose a 10% baseline tariff on all imports and additional surcharges, significantly impacting Agilent Technologies' cost structure and supply chain. Agilent's diversified global manufacturing footprint and strategic localization in China help mitigate some tariff impacts, but higher costs and competitive pressures remain concerns. Despite initial projections of modest financial impact, prolonged tariffs could necessitate further operational shifts, including relocating production and localizing R&D to maintain market access. Agilent's strong brand, advanced technology, and flexible supply chain position it to navigate tariff challenges, with potential long-term benefits from a more resilient global network. Read the full article on Seeking AlphaSeeking Alpha • Mar 01
Agilent Technologies: Recent Price Weakness Makes This Stock A Buy
Summary Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level. Read the full article on Seeking AlphaRendement pour les actionnaires
| A | US Life Sciences | US Marché | |
|---|---|---|---|
| 7D | 2.7% | 1.8% | 2.1% |
| 1Y | 9.2% | 7.7% | 30.6% |
Rendement vs Industrie: A a dépassé le secteur US Life Sciences qui a rapporté 7.7 % au cours de l'année écoulée.
Rendement vs marché: A a sous-performé le marché US qui a rapporté 30.6 % au cours de l'année écoulée.
Volatilité des prix
| A volatility | |
|---|---|
| A Average Weekly Movement | 4.1% |
| Life Sciences Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: A n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de A ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1999 | 18,000 | Padraig McDonnell | www.agilent.com |
Agilent Technologies, Inc. fournit des solutions axées sur les applications aux marchés des sciences de la vie, du diagnostic et de la chimie appliquée dans le monde entier. La société opère à travers trois segments : Life Sciences and Diagnostics Markets, Agilent CrossLab et Applied Markets. Le segment Sciences de la vie et marchés du diagnostic propose des systèmes et des composants de chromatographie liquide, ainsi que des systèmes de spectrométrie de masse par chromatographie liquide.
Agilent Technologies, Inc. Résumé des fondamentaux
| A statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$33.26b |
| Bénéfices(TTM) | US$1.29b |
| Recettes(TTM) | US$7.07b |
26.0x
Ratio P/E4.7x
Ratio P/SLe site A est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| A compte de résultat (TTM) | |
|---|---|
| Recettes | US$7.07b |
| Coût des recettes | US$3.37b |
| Marge brute | US$3.70b |
| Autres dépenses | US$2.41b |
| Les revenus | US$1.29b |
Derniers bénéfices déclarés
Jan 31, 2026
Prochaine date de publication des résultats
May 27, 2026
| Résultat par action (EPS) | 4.56 |
| Marge brute | 52.30% |
| Marge bénéficiaire nette | 18.26% |
| Ratio dettes/capitaux propres | 48.6% |
Quelles ont été les performances à long terme de A?
Voir les performances historiques et les comparaisonsDividendes
0.9%
Rendement actuel des dividendes22%
Ratio de distributionAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/07 20:55 |
| Cours de l'action en fin de journée | 2026/05/07 00:00 |
| Les revenus | 2026/01/31 |
| Revenus annuels | 2025/10/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Agilent Technologies, Inc. est couverte par 34 analystes. 17 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Charles Butler | Barclays |
| Luke Sergott | Barclays |